CytoSorbents Appoints Christopher Cramer as Vice President of Business Development

CytoSorbents Appoints Christopher Cramer as Vice President of Business
Development

MONMOUTH JUNCTION, N.J., April 15, 2013 (GLOBE NEWSWIRE) -- CytoSorbents
Corporation (OTCBB:CTSO), a critical care-focused company using blood
purification to treat life-threatening illnesses in the intensive care unit,
announced today that it has appointed Christopher Cramer, MS, MBA, as Vice
President of Business Development.

Mr. Cramer brings more than 15 years of business development and commercial
experience in the medical device field. Most recently, he was Senior Director
of New Venture Development at Johnson & Johnson (J&J), a manufacturer and
multi-national distributor of pharmaceutical, medical devices, and consumer
products with over $67 Billion in annual worldwide sales.He helped to create
and manage J&J's portfolio of early stage ventures from inception to product
launch, establishing new revenue streams for Johnson & Johnson.Chris was
personally responsible for initiating and driving significant partnership deal
flow, and has substantial experience in negotiating and establishing business
development relationships across many commercial, non-profit, and government
organizations.These deals encompassed a wide variety of structures, including
distribution, promotion, co-development, licensing, merger and acquisitions,
and equity investments.Prior to that, he was the Worldwide Strategic
Marketing leader responsible for developing and executing branding and
business development strategies for J&J's minimally invasive weight-loss
surgery division.Prior to J&J, he held multiple leadership positions at PwC
Consulting and Parametric Technology Corporation.Chris earned his BS degree
from Miami University and MBA and MS degrees from Carnegie Mellon University.

Mr. Cramer commented, "I have seen hundreds of different technologies during
my career.What is so compelling about CytoSorbents' technology is how
flexible the platform is, and how many high value therapeutic applications it
may address.I can easily envision numerous partnership opportunities for
CytoSorb® alone. But I also believe the rest of the Company's development
pipeline, including HemoDefend™, ContrastSorb, DrugSorb, and several others
that have not yet been publicly disclosed, offers the Company significant
future growth opportunities as they are monetized.I am excited by the
opportunity to join and leverage my expertise to help drive success of
CytoSorbents at this pivotal time."

"We are very excited to welcome Chris to our management team.Chris is a
seasoned and experienced senior business development executive with an
impressive track record of success in the medical device industry. With a
broad background in business development, product development, marketing,
science, and strategic consulting, Chris is the ideal person to lead and
accelerate our ongoing strategic partnership efforts," said Dr. Phillip Chan,
Chief Executive Officer of CytoSorbents."In the past several years, we have
significantly advanced two of the three major pillars of value for our Company
- commercialization of CytoSorb®, and expanding our product pipeline. In
bringing Chris on board, we have now definitively bolstered the third Company
pillar – business development and strategic partnership capability – which is
intended to drive synergy throughout our entire business."

About CytoSorbents Corporation and its Technology Pipeline

CytoSorbents Corporation is a critical care focused therapeutic device company
that specializes in blood and biological fluid purification. Its purification
technology is based on biocompatible, highly porous polymer beads that can
actively remove toxic substances from blood and other bodily fluids by pore
capture and adsorption.Some of the Company's products include:

  *CytoSorb® - The Company's flagship product is approved and sold in the
    European Union as a safe and effective cytokine blood filter, with the
    goal of preventing or treating organ failure – the leading cause of death
    in the intensive care unit with no effective therapies - in life
    threatening illnesses such as sepsis, burn injury, trauma, lung injury,
    pancreatitis, and many others.A major unmet medical need, organ failure
    costs millions of lives, and billions of dollars each year.Development of
    the next generation of CytoSorb® is being partially funded by DARPA and
    the US Army.
    
  *HemoDefend™ - Currently under advanced development, this technology is
    designed to remove non-infectious contaminants in blood transfusion
    products, such as free hemoglobin, cytokines, bioactive lipids, and
    antibodies, which significantly contribute to the millions of transfusion
    reactions and adverse outcomes, including death, each year from blood
    transfusions.
    
  *ContrastSorb -A development-stage technology designed to rapidly remove
    intravenous (IV) imaging contrast from blood that could otherwise cause
    kidney failure, or contrast-induced nephropathy, in high risk patients
    undergoing the millions of interventional radiology procedures, such as
    cardiac catheterizations, and imaging CT scans with IV contrast each year.
    
  *DrugSorb – Is a development-stage product designed to remove drugs,
    chemotherapy agents, and other chemicals from blood in drug overdose, high
    dose regional chemotherapy, chemical poisoning, and other applications.

Additional information is available on the Company's website:
http://www.cytosorbents.com.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for
the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this press
release are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ materially from
those anticipated. These statements are based on management's current
expectations and assumptions and are naturally subject to uncertainty and
changes in circumstances. We caution you not to place undue reliance upon any
such forward-looking statements. Actual results may differ materially from
those expressed or implied by the statements herein.Risk factors are detailed
in the Company's Form 10-K filed with the SEC on April 3, 2013, which is
available athttp://www.sec.gov.

CONTACT: Company Contact:
         CytoSorbents Corporation
         Dr. Phillip Chan
         Chief Executive Officer
         (732) 329-8885 ext. *823
         pchan@cytosorbents.com
        
         Investor Contact:
         Alliance Advisors, LLC
         Alan Sheinwald
         (914) 669-0222
         asheinwald@allianceadvisors.net
        
         Valter Pinto
         (914) 669-0222 x201
         valter@allianceadvisors.net
        
         Media Contact:
         JQA Partners
         Jules Abraham
         (917) 885-7378
         jabraham@jqapartners.com